The phrase "a favourable benefits" is not correct in English.
The word "favourable" is an adjective and should not be used in conjunction with the plural noun "benefits" in this way.
Example: "The new policy offers a range of benefits that are favourable to employees."
Alternatives: "advantageous benefits" or "positive benefits."
FUTURE-1 study and past studies suggest a favourable benefit-risk profile for bosentan at 2 mg/kg b.i.d., this dose is recommended for children with PAH.
Three studies showed the superiority of low molecular weight heparins in terms of a favourable benefit risk ratio in this indication [ 22- 24] in comparison to oral anticoagulants.
Despite a favourable benefit package, share of total health expenditure in GDP is minimum, increased from 3.3% of GDP in 2001 to 4.0% in 2008.
Overall, the results from the GO-MORE study suggest that adding golimumab to several different non-biological DMARD has a favourable benefit-to-risk profile in a broader RA patient population than was studied in previous clinical trials.
NSAIDs have been the cornerstone in pain management for decades, and have a favourable benefit-risk profile and attributes that distinguish them from other available analgesics, also associated with some risks.
The superiority of PEG preparations over lactulose or other osmotic laxatives demonstrated in this and other studies and the limited tolerability of stimulant laxatives in children confer a favourable benefit-risk relationship on such preparations.
The 5-year ATLAS data confirm that the early clinical improvements and safety profile seen with adalimumab in patients with AS are maintained through 5 years of treatment, supporting a favourable benefit:risk profile for the long-term use of adalimumab in patients with AS.
Despite the higher absolute risk of cardiovascular disease in these patients, however, there is no robust evidence that the use of acetylsalicylic acid (ASA) leads to a favourable benefits-to-risk balance [ 7].
Her claim that Britain had a far more favourable benefits regime was immediately challenged by Downing St, who said they were addressing such "pull factors".
18 Following the rationale that arguments for the polypill are based on the expectancy of a more favourable benefit versus safety profile, we assumed that, in a situation where a polypill would be available, it would be considered to lower the threshold for prescribing preventive medication.
GLP-1 receptor agonists have a favourable risk-benefit balance overall, which should allow the choice of drug to be individualised to each patient's needs.Amylin Pharmaceuticals (AstraZeneca).
